U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H25N7
Molecular Weight 375.4701
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ENMD-981693

SMILES

CN1CCN(CC1)C2=CC(NC3=NNC(C)=C3)=NC(\C=C\C4=CC=CC=C4)=N2

InChI

InChIKey=BLQYVHBZHAISJM-CMDGGOBGSA-N
InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+

HIDE SMILES / InChI

Molecular Formula C21H25N7
Molecular Weight 375.4701
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.casipharmaceuticals.com/investor-relations/news//entremed-stockholders-approve-name-change-to-casi-pharmaceuticals?/about-us/news/entremed-stockholders-approve-name-change-to-casi-pharmaceuticals

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor. urora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers. ENMD-2076 is tested in phase 2 clinical trials against ovarian cancer, breast cance, hepatocellular carcinoma and other malignancies.

Originator

Curator's Comment: http://www.casipharmaceuticals.com/investor-relations/news//entremed-stockholders-approve-name-change-to-casi-pharmaceuticals?/about-us/news/entremed-stockholders-approve-name-change-to-casi-pharmaceuticals

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
233 ng/mL
80 mg/m² 1 times / day multiple, oral
dose: 80 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
218 ng/mL
60 mg/m² 1 times / day multiple, oral
dose: 60 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
314 ng/mL
120 mg/m² 1 times / day multiple, oral
dose: 120 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
557 ng/mL
200 mg/m² 1 times / day multiple, oral
dose: 200 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
558 ng/mL
160 mg/m² 1 times / day multiple, oral
dose: 160 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14.66 μg × h/mL
80 mg/m² 1 times / day multiple, oral
dose: 80 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
15.26 μg × h/mL
60 mg/m² 1 times / day multiple, oral
dose: 60 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
16.74 μg × h/mL
120 mg/m² 1 times / day multiple, oral
dose: 120 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
34.5 μg × h/mL
200 mg/m² 1 times / day multiple, oral
dose: 200 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
34.6 μg × h/mL
160 mg/m² 1 times / day multiple, oral
dose: 160 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
51 h
80 mg/m² 1 times / day multiple, oral
dose: 80 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
53.1 h
60 mg/m² 1 times / day multiple, oral
dose: 60 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
44.9 h
120 mg/m² 1 times / day multiple, oral
dose: 120 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
47.6 h
200 mg/m² 1 times / day multiple, oral
dose: 200 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
46.1 h
160 mg/m² 1 times / day multiple, oral
dose: 160 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ENMD-2076 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
Discovery and development of aurora kinase inhibitors as anticancer agents.
2009 May 14
ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.
2011 Jan
Patents

Sample Use Guides

ENMD-2067 will be taken orally at a dose of 275 mg, once a day, everyday. Patients with a body surface area of less than 1.65 m2 will receive a starting dose of 250 mg, once a day, everyday.
Route of Administration: Oral
The antiproliferative effect of ENMD-2076 on adherent tumor cell lines was measured by plating 500 cells per well in a 96-well plate and incubating with 9 doses of compound, spanning 0.3 nmol/L to 125 mmol/L, for 96 hours. Cellular proliferation was measured using the sulforhodamine B (SRB; Sigma Aldrich) assay. ENMD-2076 inhibits proliferation of PANC-1, HCT116, A549 tumor cells with IC50 0.12 - 0.26 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 20:20:51 GMT 2023
Edited
by admin
on Fri Dec 15 20:20:51 GMT 2023
Record UNII
J6U9WP10T7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ENMD-981693
Common Name English
ENMD-2076 FREE BASE
Common Name English
ENMD 981693
Code English
4-PYRIMIDINAMINE, 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-((1E)-2-PHENYLETHENYL)-
Systematic Name English
(E)-N-(5-METHYL-1H-PYRAZOL-3-YL)-6-(4-METHYLPIPERAZIN-1-YL)-2-STYRYLPYRIMIDIN-4-AMINE
Systematic Name English
R-440
Code English
RO-317453
Code English
Code System Code Type Description
FDA UNII
J6U9WP10T7
Created by admin on Fri Dec 15 20:20:52 GMT 2023 , Edited by admin on Fri Dec 15 20:20:52 GMT 2023
PRIMARY
SMS_ID
300000013151
Created by admin on Fri Dec 15 20:20:52 GMT 2023 , Edited by admin on Fri Dec 15 20:20:52 GMT 2023
PRIMARY
ChEMBL
CHEMBL52885
Created by admin on Fri Dec 15 20:20:52 GMT 2023 , Edited by admin on Fri Dec 15 20:20:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID60239430
Created by admin on Fri Dec 15 20:20:52 GMT 2023 , Edited by admin on Fri Dec 15 20:20:52 GMT 2023
PRIMARY
PUBCHEM
16041424
Created by admin on Fri Dec 15 20:20:52 GMT 2023 , Edited by admin on Fri Dec 15 20:20:52 GMT 2023
PRIMARY
MESH
C551397
Created by admin on Fri Dec 15 20:20:52 GMT 2023 , Edited by admin on Fri Dec 15 20:20:52 GMT 2023
PRIMARY
CAS
934353-76-1
Created by admin on Fri Dec 15 20:20:52 GMT 2023 , Edited by admin on Fri Dec 15 20:20:52 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY